The U.S. Food and Drug Administration (FDA) granted traditional approval to donanemab (Eli Lilly), sold under the brand name Kisunla, for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease, with confirmed amyloid plaques. This is the third FDA approval granted for an Alzheimer’s treatment that changes the underlying course of the disease.
The Alzheimer’s Association statement may be accessed here. and local experts and families are available for interviews. Additionally, following is a broadcast reader:
Visuals for media: research B-roll | care & support B-roll | science images | care & support images
Nearly 7 million Americans are living with Alzheimer’s disease — a leading cause of death in the United States. Additionally, more than 11 million family members and friends provide care to people living with Alzheimer’s and other dementias. In North Carolina alone, there are more than 210,000 people living with Alzheimer’s and more than 373,000 family members and friends caring for them.
FDA Approves You can find more information at alz.org/facts. Support and information from the Alzheimer’s Association are available for free anytime, day or night, for individuals with Alzheimer’s disease and their caregivers at 800.272.3900.